遠大醫藥(00512.HK)擬斥資7372.47萬元收購武漢遠大弘元股份24.6%股權 持股將增至87%
格隆匯11月20日丨遠大醫藥(00512.HK)發佈公告，2019年11月20日，公司附屬湖北遠大生命科學與技術有限責任公司作為買方與武漢大學資產經營投資管理有限責任公司(國有企業，由武漢大學全資擁有)訂立了收購協議，據此，買方同意購入目標公司24.6%股權，累計代價為人民幣7372.47萬元，將會由買方以現金支付。待完成後，買方將會持有目標公司約87%股權。
武漢遠大弘元股份有限公司(“目標公司”)為一間在2000年成立的股份制有限責任公司，註冊股本是人民幣5000萬元，並已全額繳足。集團於2008年至2010年期間完成一系列的交易並累計購入62.4%目標公司的股權。自此，集團成為目標公司最大股東，而賣方持24.6%股權為其第二大股東。
目標公司專注氨基酸及其衍生物的研發及生產，並受惠於武漢大學及湖北省氨基酸工程技術研究中心的研究成果，致力於生物醫學領域產品的高新技術產業化。目標公司擁有嚴謹的品質保證體系，通過了多項中國及國際性的品質管理系統認證。目標公司亦為氨基酸國家標準和行業標準的起草單位，其產品質量管理系統已根據多個國際性及本地品質標準被核證。目標公司擁有進行進出口業務的授權證照。
其品牌“WUBC”和“WHUHOYO”為氨基酸領域中的國際性知名品牌。目標公司已通過中國最新版的GMP認證，現擁有乙酰酪氨酸、乙酰半胱氨酸、鹽酸半胱氨酸、羧甲司坦、鹽酸精氨酸、鹽酸組氨酸、鹽酸賴氨酸等多個生產批文，另有數個新產品的生產批文正在審批之中。於公告日期，目標公司由買方持有62.4%、賣方持有24.6%、兩名獨立第三方(除持有目標公司股權或為目標公司董事外)分別持有10%及3%。
公告表示，自集團收購了目標公司的62.4%權益後，目標公司展示了健康的增長及可靠的前景。董事會相信收購事項將可使集團增加於目標公司的股權及整合對目標公司的控制，以成為中國最大的半胱胺酸生產商之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
